Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.

  • Revenue in USD (TTM)53.98bn
  • Net income in USD13.91bn
  • Incorporated1970
  • Employees68.00k
  • Location
    Merck & Co Inc2000 Galloping Hill RdKENILWORTH 07033-1310United StatesUSA
  • Phone+1 (908) 740-4000
  • Fax+1 (908) 423-1987
  • Websitehttp://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRK:NYQ since
announced
Transaction
value
Acceleron Pharma IncDeal completed30 Sep 202130 Sep 2021Deal completed24.96%11.59bn
Data delayed at least 15 minutes, as of May 23 2022 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amgen, Inc.26.32bn5.72bn133.04bn24.20k24.52145.2414.595.0610.1610.1646.561.710.43241.555.541,087,438.009.4011.0711.9313.4075.2179.2921.7530.881.096.640.975849.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co46.96bn6.25bn163.30bn32.20k27.235.179.683.482.822.8221.1514.830.43594.726.551,458,385.005.822.677.163.2979.6274.1813.356.541.236.750.587163.849.0919.01177.589.43-4.355.22
Merck & Co., Inc.53.98bn13.91bn237.28bn68.00k17.115.8013.704.405.485.5921.2816.170.54662.565.98793,794.1014.097.6118.7210.1471.1170.9225.7816.061.1442.760.43786.0617.314.12173.1825.7922.487.49
AbbVie Inc56.73bn12.40bn261.59bn50.00k21.2316.0612.524.616.976.9731.919.220.38635.085.581,134,500.008.507.4610.909.4669.7872.0322.0118.110.7088.540.818397.8922.6916.99151.7114.1310.4417.93
Eli Lilly And Co29.32bn6.13bn287.52bn35.00k44.9130.8137.049.816.746.7432.239.820.62551.994.92837,794.3013.0711.0817.9415.8074.4077.1620.9020.770.97659.830.635753.7515.405.94-9.8815.3111.4010.76
Pfizer Inc.92.37bn25.42bn296.70bn79.00k11.923.599.693.214.434.3616.1114.740.53913.968.001,169,203.0014.866.6218.438.2560.4574.0427.5621.321.1381.490.305175.7295.169.00238.0525.516.285.39
Data as of May 23 2022. Currency figures normalised to Merck & Co Inc's reporting currency: US Dollar USD

Institutional shareholders

26.99%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2022205.87m8.14%
BlackRock Fund Advisorsas of 31 Mar 2022128.16m5.07%
SSgA Funds Management, Inc.as of 31 Mar 2022118.32m4.68%
Wellington Management Co. LLPas of 31 Mar 202245.70m1.81%
Geode Capital Management LLCas of 31 Mar 202244.41m1.76%
Charles Schwab Investment Management, Inc.as of 31 Mar 202230.08m1.19%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202229.74m1.18%
Massachusetts Financial Services Co.as of 31 Mar 202228.84m1.14%
BlackRock Investment Management (UK) Ltd.as of 31 Mar 202227.31m1.08%
Norges Bank Investment Managementas of 31 Dec 202123.79m0.94%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.